Provention Bio Inc

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Their predict and prevent model is focused on developing novel therapeutic approaches that intervene before the target disease begins, re-appears, or progresses.  Provention Bio offers the potential to reduce the high morbidity, mortality, patient suffering, and escalating costs of chronic autoimmune and inflammatory diseases, such as type 1 diabetes (T1D), Crohn’s disease, ulcerative colitis, and emerging viral infections. They believe Provention’s business model, coupled with its expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials, will enable them to in-license and efficiently partner both early-stage development assets and more advanced clinical-stage opportunities.

Provention Bio, Inc. (PRVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Decline

Sanofi

Hart-Scott- Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc. Paris, France – April 26 , 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi's proposed acquisition of Provention Bio, Inc. (“Provention Bio”, NASDAQ: PRVB) has expired. On March 24, 2023, Sanofi commenced a cash tender offer (the “Offer”) to purchase all outstanding shares of common stock of Provention Bio (the “Shares”), for $25.00 per Share, to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law.

Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

C3.ai

BridgeBio Pharma Inc

Comerica

Enovix Corporation

First Republic

LifeStance Health Group

UMB Financial

Western Alliance Bancorporation

Zions Bancorp

March was a good month for the stock market, with the S&P 500 gaining about 3.5%.

The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Provention will receive only $25.00 in cash for each share of Provention that they own.

PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.

Why Provention Bio Stock Skyrocketed 256% This Week

Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.

Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi

NEW YORK , March 14, 2023 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Provention Bio, Inc. (NASDAQ: PRVB), relating to its proposed sale to Sanofi. Under the terms of the agreement PRVB shareholders are expected to receive $25.00 in cash per share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB

Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.

This biopharma stock jumped over 250% on Monday: what happened?

Seagen

Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.

Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners

MILWAUKEE , March 13, 2023 /PRNewswire/ -- Ademi LLP is investigating Provention Bio (Nasdaq: PRVB) for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.  Click here to learn how to join the action https://www.ademilaw.com/case/provention-bio-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi

French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or a total equity value of about $2.9 billion. Provention Bio's stock surged more than 250% in early trading on Monday, while shares of Sanofi slipped 1%.

Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Provention Bio, Inc. (NASDAQ: PRVB) to Sanofi for $25.00 per share in cash is fair to Provention shareholders. Halper Sadeh encourages Provention shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders

Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per share in cash.

Why Is Provention Bio (PRVB) Stock Up 263% Today?

RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.

Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.

Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)

The biopharmaceutical company agrees to be acquired by France's Sanofi for $25 a share, or about $2.9 billion.

Provention Bio Stock Soars on $2.9 Billion Acquisition by Sanofi

French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with an equity value of $2.9 billion. The deal will allow Sanofi to add to its portfolio, TZIELD, which was approved in the U.S. last year as the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D).

Sanofi to buy Provention Bio in deal worth $2.9 billion

France's Sanofi has agreed to acquire Provention Bio for $2.9 billion to bolster its work on type 1 diabetes therapy and to strengthen its drug pipeline following development setbacks.

Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal

Sanofi to acquire Proventio n Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)

Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know

RED BANK, N.J. , March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a new  non-executive employee to purchase an aggregate of 10,000 shares of common stock.

Provention Bio Announces the Grant of Inducement Awards

RED BANK, N.J. , Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets.

Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

PRVB got its teplizumab approved last year. The molecule is a wonderful new addition to T1D therapy; however, it has been in development for decades.

Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry

Novavax

There is an argument for hitting the buy button, but it's important to consider the potential risks too.

2 Beaten-Down Stocks That Might Be too Cheap to Ignore

Provention Bio, Inc. (PRVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

News for Provention Bio Inc Stock (PRVB)